Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Diane Allingham-Hawkins"'
Publikováno v:
BMC Medical Genetics, Vol 18, Iss 1, Pp 1-5 (2017)
Abstract Background Studying human genome using chromosomal microarrays has significantly improved the accuracy and yield of diagnosing genomic disorders. Chromosome 7q36 deletions and duplications are rare genomic disorders that have been reported i
Externí odkaz:
https://doaj.org/article/30059f30def5478cac23aafd6331f35d
Publikováno v:
Genetics in Medicine. 24:S254
Autor:
Pamela J. Goodwin, Paul E. Goss, Corinne Serruya, Steven A. Narod, Lisa Di Prospero, Ellen Warner, Meri Klein, Hilmi Ozcelik, John Blondal, Gordon Glendon, Jean-Sébastien Brunet, Roxana Moslehi, Wendy S. Meschino, Velita Contiga, Colleen Paterson, Joanne Honeyford, Nancy Hamel, William D. Foulkes, Alexander Liede, Diane Allingham-Hawkins
Publikováno v:
JNCI Journal of the National Cancer Institute. 91:1241-1247
Approximately 2.0%-2.5% of Ashkenazi Jewish women carry one of three founding mutations in the BRCA1 and BRCA2 genes, and each mutation is associated with a high lifetime risk of invasive breast cancer. We investigated the extent to which these three
Publikováno v:
PLoS Currents
It is estimated that approximately 22,000 Americans will be diagnosed with tumor of the brain or nervous system in 2010. Among primary brain tumors, approximately 60% are gliomas, the most common and most malignant of which is glioblastoma multiforme
Publikováno v:
PLoS Currents
Coronary artery disease (CAD) is a leading cause of death worldwide and in the United States it is responsible for more than 500,000 deaths each year. Genome-wide association studies (GWAS) have revealed connections between a number of common single
Publikováno v:
Advances in Genomics and Genetics. :115
Publikováno v:
PLoS Currents
Worldwide, lung cancer accounts for approximately 1 million deaths each year, making it the most common cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is often associated
BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
Publikováno v:
PLoS Currents
Colon and rectal cancer (CRC) are the third most common cancer in the United States and cause approximately 50,000 deaths per year. The anti–epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (Erbitux®) and panitumumab (Vectib